News
ADDF reflects on Eli Lilly’s donanemab
The Alzheimer’s Drug Discovery Foundation (ADDF) is optimistic about the positive data reported by Eli Lilly and Company regarding its anti-amyloid therapy, donanemab.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The Alzheimer’s Drug Discovery Foundation (ADDF) is optimistic about the positive data reported by Eli Lilly and Company regarding its anti-amyloid therapy, donanemab.